LiquID Guide Catheter Extension Safety Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: John Schultz
- Email: jschultz223@gmail.com
Study Locations
-
-
-
Genk, Belgium
- Ziekenhuis Oost-Limburg
-
-
-
-
-
Cork, Ireland
- Mater Private
-
Dublin, Ireland
- Mater Private
-
Galway, Ireland
- Galway University Hospital
-
-
-
-
-
Bristol, United Kingdom
- University Hospitals Bristol
-
Edinburgh, United Kingdom
- Royal Edinburgh
-
Glasgow, United Kingdom
- Golden Jubilee
-
London, United Kingdom
- St. George's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria - participants must be:
- scheduled for non-emergent, percutaneous coronary procedure in which the use of a guide catheter extension is anticipated
- able to provide informed consent to participate in the study
Exclusion Criteria - participants must not have:
- evidence of ongoing ST-elevation myocardial infarction (STEMI) or STEMI treatment for late presentation STEMI with index admission (stabilized acute coronary syndrome allowed)
- left ventricular ejection fraction <20%
- required intervention in a saphenous vein graft
- an intolerance or known allergy to medications/contrast expected to be used during the procedure or during hospital stay
- had a cardiac intervention within two weeks of the procedure
- renal insufficiency (serum creatinine of > 2.3 mg/dl)
- active gastrointestinal bleeding
- an active infection or fever (>37.8º C) that may be due to infection
- significant anemia (hemoglobin < 8.0 mg / dl)
- severe uncontrolled systemic hypertension (systolic press. > 240 mm Hg within the past month)
- a severe electrolyte imbalance
- congestive heart failure (NYHA Class IV)
- presented with an acute coronary syndrome where serum troponin concentrations have not been demonstrated to be declining prior to the scheduled procedure (within the past two weeks)
- uncontrolled diabetes (> 2 serum glucose concentrations of > 350 mg/dl within the past 7 days)
- participation in an investigational protocol
- unwillingness or inability to comply with any protocol requirements
- angina, or ischemia caused by occluded artery
- other clinical conditions, that in the opinion of the investigator significantly compromise the ability to perform a safe and/or effective procedure
Vulnerable Population Exclusion - participants must not be:
- under 18 years old
- pregnant or nursing
- immuno-compromised
- over 89 years old
- incapacitated, mentally compromised or otherwise incapable of understanding and/or providing informed consent (including emergency situations)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LiquID GCE Use
|
Use of the LiquID GCE to aid in percutaneous coronary intervention (PCI)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Number of Participants With In-hospital Major Adverse Cardiac Events (MACE)
Time Frame: 48 hours or discharge (whichever comes first)
|
|
48 hours or discharge (whichever comes first)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Number of Participants With Device Oriented Clinical Outcome
Time Frame: 1 Day
|
Successful deployment and retrieval of the LiquID device without any device deficiencies or where use of the LiquID device directly leads to a MACE, target vessel dissection, longitudinal stent deformation or proximal collar stent stripping.
|
1 Day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Peter Henriksen, BSc, MB ChB, PhD, FRCP, Royal Edinburgh
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 200-0004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.